[Bendamustine plus rituximab as first-line treatment in patients with indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma : a real-world study in China]

Zhonghua Xue Ye Xue Za Zhi. 2023 Apr 14;44(4):333-336. doi: 10.3760/cma.j.issn.0253-2727.2023.04.012.

[Article in Chinese]

Authors

K X Du¹, H R Shen¹, L Wang¹, J H Liang¹, J Z Wu¹, Y Li¹, Y Xia¹, H Yin¹, J Y Li¹, W Xu¹

Affiliation

¹ The First Affiliated Hospital of Nanjing Medical University (Department of Hematology, Jiangsu Province Hospital), Nanjing 210029, China.

PMID: 37357004
PMCID: PMC10282863
DOI: 10.3760/cma.j.issn.0253-2727.2023.04.012

No abstract available

MeSH terms

Adult
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bendamustine Hydrochloride / therapeutic use
Humans
Lymphoma, B-Cell* / drug therapy
Lymphoma, B-Cell* / etiology
Lymphoma, B-Cell* / pathology
Lymphoma, Mantle-Cell* / drug therapy
Lymphoma, Non-Hodgkin* / drug therapy
Rituximab / therapeutic use

Substances

Rituximab
Bendamustine Hydrochloride